Quantitative morphological magnetic resonance imaging follow-up of low-grade glioma: A plea for systematic measurement of growth rates

Neurosurgery

Volumn 71, Issue 3, 2012, Pages 729-739

  Pallud, Johan ^a,b,k   Taillandier, Luc ^c,k   Capelle, Laurent ^d,k   Fontaine, Denys ^e,k   Peyre, Matthieu ^b,f   Ducray, François ^g   Duffau, Hugues ^h   Mandonnet, Emmanuel ^b,i,j,k  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Nancy Neurological Hospital Nancy   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e PASTEUR HOSPITAL   (France)

^f BEAUJON HOSPITAL   (France)

^g HÔPITAL NEUROLOGIQUE   (France)

^h MONTPELLIER UNIVERSITY HOSPITAL   (France)

ⁱ HÔPITAL LARIBOISIÈRE   (France)

^j Centre National de la Recherche Scientifique   (France)

^k UMR 8165 ^*  (France)

more..

Author keywords

Glioma growth rates; Low grade glioma; Quantitative MRI follow up

Indexed keywords

CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME DELETION; FOLLOW UP; GLIOMA; HUMAN; INSULA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TUMOR GROWTH; TUMOR VOLUME; WHITE MATTER;

DISEASE PROGRESSION; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM GRADING; PROGNOSIS; SUPRATENTORIAL NEOPLASMS;

EID: 84865741381     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e31826213de     Document Type: Review

References (53)

1. Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol. 2010;17(9): 1124-1133.
2. Duffau H. Lessons from brain mapping in surgery for low-grade glioma: insights into associations between tumour and brain plasticity. Lancet Neurol. 2005;4(8): 476-486.
3. Wessels PH, Weber WE, Raven G, Ramaekers FC, Hopman AH, Twijnstra A. Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol. 2003;2(7):395-403.
4. Duffau H. Surgery of low-grade gliomas: towards a 'functional neurooncology'. Curr Opin Oncol. 2009;21(6):543-549.
5. McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008;63(4):700-707; author reply 707-708.
6. Pouratian N, Asthagiri A, Jagannathan J, Shaffrey ME, Schiff D. Surgery Insight: the role of surgery in the management of low-grade gliomas. Nat Clin Pract Neurol. 2007;3(11):628-639.
7. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62(4):753-764; discussion 764-766.
8. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the longterm outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26(8): 1338-1345.
9. Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Adv Tech Stand Neurosurg. 2010;35:65-79.
10. Brasil Caseiras G, Ciccarelli O, Altmann DR, et al. Low-grade gliomas: six-month tumor growth predicts patient outcome better than admission tumor volume, relative cerebral blood volume, and apparent diffusion coefficient. Radiology. 2009; 253(2):505-512.
11. Danchaivijitr N,Waldman AD, Tozer DJ, et al. Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? Radiology. 2008;247(1):170-178.
12. Guillevin R, Menuel C, Abud L, et al. Proton MR spectroscopy in predicting the increase of perfusion MR imaging for WHO grade II gliomas. J Magn Reson Imaging. 2012;35(3):543-550.
13. Guillevin R,Menuel C, DuffauH, et al. Proton magnetic resonance spectroscopy predicts proliferative activity in diffuse low-grade gliomas. J Neurooncol. 2008;87(2):181-187.
14. Hlaihel C, Guilloton L, Guyotat J, Streichenberger N, Honnorat J, Cotton F. Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas. J Neurooncol. 2010;97(1):73-80.
15. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003;24(10): 1989-1998.
16. McKnight TR, Lamborn KR, Love TD, et al. Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas. J Neurosurg. 2007;106(4):660-666.
17. Bian W, Khayal IS, Lupo JM, et al. Multiparametric characterization of grade 2 glioma subtypes using magnetic resonance spectroscopic, perfusion, and diffusion imaging. Transl Oncol. 2009;2(4):271-280.
18. Bynevelt M, Britton J, Seymour H, MacSweeney E, Thomas N, Sandhu K. FLAIR imaging in the follow-up of low-grade gliomas: time to dispense with the dualecho? Neuroradiology. 2001;43(2):129-133.
19. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg. 1987;66(6):865-874.
20. Pallud J, Varlet P, Devaux B, et al. Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities. Neurology. 2010;74(21):1724-1731.
21. Price SJ, Jena R, Burnet NG, et al. Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study. AJNR Am J Neuroradiol. 2006;27(9):1969-1974.
22. Stadlbauer A, Buchfelder M, Doelken MT, Hammen T, Ganslandt O. Magnetic resonance spectroscopic imaging for visualization of the infiltration zone of glioma. Cent Eur Neurosurg. 2011;72(2):63-69.
23. Mandonnet E, Delattre JY, Tanguy ML, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003;53(4):524-528.
24. Mandonnet E, Pallud J, Clatz O, et al. Computational modeling of the WHO grade II glioma dynamics: principles and applications to management paradigm. Neurosurg Rev. 2008;31(3):263-269.
25. Mandonnet E, Pallud J, Fontaine D, et al. Inter-and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection. Neurosurg Rev. 2010;33(1):91-96.
26. Pallud J, Mandonnet E, Duffau H, et al. Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol. 2006;60(3):380-383.
27. Peyre M, Cartalat-Carel S, Meyronet D, et al. Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol. 2010;12(10):1078-1082.
28. Ricard D, Kaloshi G, Amiel-Benouaich A, et al. Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol. 2007;61(5):484-490.
29. Sorensen AG, Patel S, Harmath C, et al. Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol. 2001;19(2):551-557.
30. Kier EL, Staib LH, Davis LM, Bronen RA. MR imaging of the temporal stem: anatomic dissection tractography of the uncinate fasciculus, inferior occipitofrontal fasciculus, and Meyer's loop of the optic radiation. AJNR Am J Neuroradiol. 2004; 25(5):677-691.
31. Mandonnet E, Capelle L, Duffau H. Extension of paralimbic low grade gliomas: toward an anatomical classification based on white matter invasion patterns. J Neurooncol. 2006;78(2):179-185.
32. Matsukado Y, Maccarty CS, Kernohan JW. The growth of glioblastoma multiforme (astrocytomas, grades 3 and 4) in neurosurgical practice. JNeurosurg. 1961;18(5):636-644.
33. Pallud J, Devaux B, Daumas-Duport C, Oppenheim C, Roux FX. Glioma dissemination along the corticospinal tract. J Neurooncol. 2005;73(3):239-240.
34. Chen X, Dai J, Jiang T. Supratentorial WHO grade II glioma invasion: a morphologic study using sequential conventional MRI. Br J Neurosurg. 2010; 24(2):196-201.
35. Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera P, Chodkiewicz JP. Oligodendrogliomas. Part I: patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neurooncol. 1997;34(1):37-59.
36. Pallud J, Llitjos JF, Dhermain F, et al. Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol. 2012;14(4):495-505.
37. Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Ann Neurol. 2010;68(5):727-733.
38. Potts MB, Smith JS, Molinaro AM, Berger MS. Natural history and surgical management of incidentally discovered low-grade gliomas. J Neurosurg. 2012;116 (2):365-372.
39. Pallud J, Mandonnet E. Progressive low-grade glioma. J Neurosurg. 2012. In press.
40. Goze C, Bezzina C, Goze E, et al. 1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth. J Neurooncol. 2012;108(1):69-75.
41. Isla A, Alvarez F, Gonzalez A, Garcia-Grande A, Perez-Alvarez M, Garcia-Blazquez M. Brain tumor and pregnancy. Obstet Gynecol. 1997;89(1): 19-23.
42. Pallud J, Duffau H, Razak RA, et al. Influence of pregnancy in the behavior of diffuse gliomas: clinical cases of a French glioma study group. J Neurol. 2009;256 (12):2014-2020.
43. Pallud J,Mandonnet E, Deroulers C, et al. Pregnancy increases the growth rates of World Health Organization grade II gliomas. Ann Neurol. 2010;67(3):398-404.
44. Pallud J, Capelle L, Mandonnet E. Comment on parameters of low-grade glioma as predictors. Radiology. 2010;256(3):1014.
45. Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance imaging: systematic review and optimal treatment paradigm. Neurosurg Focus. 2011;31(6):E12.
46. Chang EF, Clark A, Jensen RL, et al. Multiinstitutional validation of the University of California at San Francisco low-grade glioma prognostic scoring system. Clinical article. J Neurosurg. 2009;111(2):203-210.
47. Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg. 2008;109(5): 817-824.
48. Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer. 1994;74(6):1784-1791.
49. Perry JR, Cairncross JG. Glioma therapies: how to tell which work? J Clin Oncol. 2003;21(19):3547-3549.
50. Angelini ED, Delon J, Bah AB, Capelle L, Mandonnet E. Differential MRI analysis for quantification of low grade glioma growth. Med Image Anal. 2012; 16(1):114-126.
51. Angelini ED, Clatz O, Mandonnet E, Konukoglu E, Capelle L, Duffau H. Glioma dynamics and computational models: a review of segmentation, registration, and in silico growth algorithms and their clinical applications. Curr Med Imaging Rev. 2007;3(4):425-437.
52. Harpold HL, Alvord EC Jr, Swanson KR. The evolution of mathematical modeling of glioma proliferation and invasion. J Neuropathol Exp Neurol. 2007;66 (1):1-9.
53. Konukoglu E, Clatz O, Menze BH, et al. Image guided personalization of reactiondiffusion type tumor growth models using modified anisotropic eikonal equations. IEEE Trans Med Imaging. 2010;29(1):77-95.